Marije B. Overdijk

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma.

DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma.

Journal: eLife

Published: July 20, 2026

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Journal: Molecular cancer therapeutics

Published: January 13, 2026

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Journal: Clinical and translational science

Published: November 24, 2025

Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Journal: Blood cancer journal

Published: February 16, 2025

Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells.

Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells.

Journal: Journal of oncology

Published: August 13, 2021

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.

Journal: Blood advances

Published: November 02, 2020

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies.

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies.

Journal: HemaSphere

Published: August 03, 2020

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.

Journal: Molecular cancer therapeutics

Published: January 17, 2020

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

Journal: Blood cancer journal

Published: November 05, 2019

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: June 15, 2015

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Journal: mAbs

Published: March 12, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026